



Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

Guideline

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases

Publisher

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Alexanderplatz 1
D-10178 Berlin

Executive chairman: Prof. Dr. med. Carsten Bokemeyer

Phone: +49 (0)30 27 87 60 89 - 0

Fax: +49 (0)30 27 87 60 89 - 18

info@dgho.de

www.dgho.de

Contact person

Prof. Dr. med. Bernhard Wörmann
Medical superintendent

Source

www.onkopedia-guidelines.info

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

Table of contents

1 Definition and Basic Information	2
2 Prevention of Catheter-Related Infections	2
3 Diagnosis	3
3.1 Diagnostic Criteria	3
3.2 Diagnostics	4
4 Therapy	4
4.1 Antimicrobial Therapy	4
4.2 Management of CVC	5
5 References	5
7 Links	5
8 Authors' Affiliations	5
9 Disclosure	8

Central Venous Catheter-related Infections (CRI) in Hematology and Oncology

Status: January 2012

Authors: Hans-Heinrich Wolf, Malte Leithäuser, Georg Maschmeyer, Hans-Jürgen Salwender, Ulrike Klein, Iris Chaberny, Florian Weissinger, Dieter Buchheidt, Markus Ruhnke, Gerlinde Egerer, Oliver A. Cornely, Gerd Fätkenheuer, Sabine Mousset

on behalf of the AGIHO Infectious Diseases Working Party of the DGHO

1 Definition and Basic Information

Insertion of central venous catheters is a common procedure in the treatment of patients with hematologic malignancies and solid tumors. Catheter-related infections (CRI) cause considerable morbidity. They are also one of the differential diagnoses of fever of unknown origin in neutropenic patients. This guideline on diagnostics and therapy of CRI was developed by the AGIHO Infectious Diseases Working Party of the DGHO.

Categories are based on the evaluation of study results and the recommendations developed by the Infectious Diseases Society of America, ISDA, see [Table 1](#).

Table 1: Categories of Evidence

Category, grade Strength of Recommendation	Definition
A	Good evidence to support a recommendation for use
B	Moderate evidence to support a recommendation for use
C	Poor evidence to support a recommendation for use
D	Moderate evidence to support a recommendation against use
E	Good evidence to support a recommendation against use
Quality of Evidence	Definition
I	Evidence from ≥ 1 properly randomized, controlled trial
II	Evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferable from > 1 centre); from multiple time series; or from dramatic results of uncontrolled experiments
III	Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports from expert committees

2 Prevention of Catheter-Related Infections

Recommendations are summarized in [Table 2](#).

Table 2: Prevention of Catheter-Related Infections

Recommendation	Category of Evidence
Access via the subclavian vein is associated with a lower CRI rate as compared to internal jugular vein	A-I
Compliance with hygiene principles during insertion and standardized aseptic placement help to avoid infections	A-I
Impregnation of CVCs with antiseptics (chlorhexidine/silver sulfadiazine) or antibiotics (minocycline/rifampicin) reduces incidence of catheter colonization	A-I
Education programs for nurses and physicians help to reduce the incidence of CRI	A-II
Ultrasound-guided placement helps to reduce CRI rates	B-I
Alcoholic chlorhexidine solution, alcoholic polyvidone-iodine solutions or 70% propanolol should be used for disinfection of the catheter insertion site	A-I
More frequent replacement does not reduce the incidence of infection	D-I
Systemic prophylactic antibiotic treatment prior to catheter insertion is not recommended	E-I
Topical application of antibiotic ointments for reducing staphylococcal colonization at the catheter insertion site and as a nasal ointment is not recommended	E-I

3 Diagnosis

3.1 Diagnostic Criteria

In clinical practice, diagnosis of central venous catheter-related infections is based on symptoms and test results not always withstanding strict definitions. In many cases, CRI can only be presumed backed-up by clinical symptoms and test results listed in [Table 3](#).

Table 3: Diagnostic Criteria for CRI

Diagnosis	Criteria
Definite CRI	<ul style="list-style-type: none"> Pathogen detected at the catheter tip by a standard method plus same pathogen with the same susceptibility pattern detected in blood culture <p>and / or</p> <ul style="list-style-type: none"> DTTP¹ > 2 h <p>and / or</p> <ul style="list-style-type: none"> CFU Ratio² ≥ 10
Probable CRI	<ul style="list-style-type: none"> Local infection at the insertion site <p>and / or</p> <ul style="list-style-type: none"> Remission of previously refractory fever within 48h after catheter removal plus positive blood culture <p>and / or</p> <ul style="list-style-type: none"> Colonization of the catheter tip³
Possible CRI	<ul style="list-style-type: none"> Pathogen detected in blood culture that is typically implicated in causing catheter infections (<i>S. epidermidis</i>, <i>S. aureus</i> or other coagulase - negative Staphylococci, <i>Candida</i> spp.) <p>and / or</p> <ul style="list-style-type: none"> Positive blood culture and no other focus identified in a patient with an indwelling central venous catheter (CVC)

Legend:

¹ DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;

² CFU Ratio – Ratio of Colony Forming Units between pathogen detected in quantitative catheter and peripheral blood cultures;

³ Results above the limit specified for the method

3.2 Diagnostics

Recommendations are summarized in [Table 4](#).

Table 4: Diagnostics of Central Venous CRIs

Recommendation	Category of Evidence
One pair of blood cultures (aerobic and anaerobic) to be taken from the catheter and one from a peripheral vein for microbiological evaluation	A-II
DTTP ¹ for routine diagnostic purposes	A-I
Semiquantitative culturing for microbiological diagnosis of CRI after catheter removal	A-II
Quantitative culturing from the interior surface of the catheter, vortex and ultrasound treatment of the catheter to disengage adhesive bacteria	A-II
Endoluminal brushing if blood cultures cannot be drawn via CVC line	C-II
Ultrasound imaging along the catheter tunnel for diagnosis of CRI	C-III
Blood cultures from all lumina of the catheter	C-III
No cultures from the catheter hub	D-II
No skin swab for diagnosis of CRI	D-II
No placing of the catheter tip in broth and subsequently culturing the pathogen	E-II

Legend:

¹ DTTP (Differential Time To Positivity) – Difference in time between positivity of results of catheter culture and peripheral blood culture;

4 Therapy

First goal is the successful treatment of CRI using systemic antimicrobial therapy. Second goal is the prevention of secondary infection.

4.1 Antimicrobial Therapy

Recommendations are summarized in [Table 5](#).

Table 5: Antimicrobial Therapy in CRI

Recommendation	Category of Evidence
Antimicrobial treatment of suspected CRI based on the same principles as treatment of fever of unknown origin (FUO)	
Prompt empirical vancomycin therapy is not required	A-II

At least 2 weeks of systemic antimicrobial treatment in immunosuppressed patients	B-III
For <i>in vitro</i> susceptible pathogens, therapy with a penicillinase-resistant penicillin is more effective and, therefore, preferable to treatment with glycopeptide antibiotics	B-II
Antibiotic lock in addition to systemic antibiotic therapy has shown to reduce the relapse rate of CRI	C-III

4.2 Management of CVC

Recommendations are summarized in [Table 6](#).

Table 6: Management of CVC

Recommendation	Category of Evidence
Primary catheter removal is necessary in <ul style="list-style-type: none"> • CRI due to <i>Staphylococcus aureus</i> • CRI due to <i>Candida</i> spp. • Tunnel or pocket infection • Complicated CRI (e.g. metastatic organ or severe soft tissue infections) 	A-II B-II B-III B-II
Preservation of CVC may be initially attempted in clinically stable patients in the presence of the following pathogens <ul style="list-style-type: none"> • Coagulase-negative Staphylococci • <i>Corynebacterium jeikeium</i> • <i>Acinetobacter baumannii</i> • <i>Stenotrophomonas maltophilia</i> • <i>Pseudomonas aeruginosa</i> • <i>Bacillus</i> spp. 	B-III

5 References

1. Wolf H. H. al.: Central venous catheter-related infections in hematology and oncology. *Ann Hematol* 2008;87:863-876. DOI:10.1007/s00277-008-0509-5

7 Links

<https://www.agiho.de/ueber-die-agiho>

8 Authors' Affiliations

Dr. med. Hans-Heinrich Wolf

Universitätsklinikum Halle

Innere Medizin IV

Ernst-Grube-Str. 40

06120 Halle

Tel: 0345 557-3273

Fax: 0345 557-2950

hans.wolf@medizin.uni-halle.de

Dr. med. Malte Leithäuser

Gemeinschaftspraxis
Lakner/Decker/Leithäuser
Wismarische Str. 32
18057 Rostock
Tel: 0381 4997999
Fax: 0381 4934276
mleith@gmx.de

Prof. Dr. med. Georg Maschmeyer

Klinikum Ernst von Bergmann Potsdam
Klinik für Hämatologie, Onkologie
und Palliativmedizin
Charlottenstr. 72
14467 Potsdam
Tel: 0331 2416001
Fax: 0331 2416000
gmaschmeyer@klinikumebv.de

Dr. med. Hans-Jürgen Salwender

Asklepios Klinik Hamburg-Altona
II. Medizinische Abteilung
Hämatologie / Stammzelltransplantation
Paul-Ehrlich-Str. 1
22763 Hamburg
Tel: 040 181881-1211
Fax: 040 181881-4904
h.salwender@asklepios.com

Dr. med. Ulrike Klein

Universitätsklinikum Heidelberg
Kaufmännische Leitung UFHK und ZKJM
Im Neuenheimer Feld 430
69120 Heidelberg
Ulrike.Klein2@med.uni-heidelberg.de

Prof. Dr. med. Iris Chaberny

Universitätsklinikum Leipzig AöR
Institut für Hygiene /
Krankenhaushygiene
Johannesallee 34, Haus L
04103 Leipzig
Iris.Chaberny@medizin.uni-leipzig.de

Prof. Dr. med. Florian Weissinger

Evangelisches Krankenhaus Bielefeld
Klinik für Innere Medizin
Hämatologie / Onkologie und Palliativmedizin
Schildescher Str. 99
33611 Bielefeld
Tel: 0521 772-75504
Fax: 0521 772-75505
florian.weissinger@evkb.de

Prof. Dr. med. Dieter Buchheidt

Klinikum Mannheim GmbH
Medizinische Fakultät Mannheim
III. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Tel: 0621 383-4110
Fax: 0621 383-4201
dieter.buchheidt@umm.de

Prof. Dr. med. Markus Ruhnke

Paracelsus-Klinik Osnabrück
MVZ Hämatologie/Onkologie
Am Natruper Holz
49076 Osnabrück

Prof. Dr. med. Gerlinde Egerer

Universitätsklinikum Heidelberg
Medizinische Klinik V
Hämatologie/Onkologie
Im Neuenheimer Feld 410
69120 Heidelberg
Tel: 06221 56-8002
Fax: 06221 56-6562
gerlinde.egerer@med.uni-heidelberg.de

Prof. Dr. med. Oliver A. Cornely

Uniklinik Köln, Klinik I für Innere Med.
Zentrum für Klinische Studien
Infektiologie-Hämatologie-Onkologie
Kerpener Str. 62
50937 Köln
Tel: 0221 478-6494
Fax: 0221 478-3611
oliver.cornely@zks-koeln.de

Prof. Dr. med. Gerd Fätkenheuer

Universität zu Köln

I. Medizinische Klinik

Joseph-Stelzmann-Str. 9

50924 Köln

Tel: 0221 478-4886

Fax: 0221 478-3424

G.Faetkenheuer@uni-koeln.de

Dr. Sabine Mousset

9 Disclosure

according to the rules of the German Association of Hematology and Oncology (DGHO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie) and the recommendations of the AWMF (version dated April 23, 2010) and international recommendations.